Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
PeptiDreamPPTDF 76 Debt-to-Equity is 0.33 as of Mar. 2026, which is 35% below its 10-year median of 0.51. GuruFocus rates PPTDF with a GF Score™ of 76/100 and a GF Value™ of $10.57 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 965 Biotechnology companies, PeptiDream ranks worse than 64.87% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for PeptiDream's Debt-to-Equity or its related term are showing as below:
PPTDF'
s Debt-to-Equity Range Over the Past 10 Years
Min: 0.33 Med: 0.51 Max: 0.9
Current: 0.33
During the past 13 years, the highest Debt-to-Equity Ratio of PeptiDream was 0.90. The lowest was 0.33. And the median was 0.51.
PPTDF's Debt-to-Equity is ranked worse than 64.87% of 965
companies
in the Biotechnology industry
Industry Median: 0.16
vs PPTDF: 0.33
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
PeptiDream Debt-to-Equity Related Terms
PeptiDream Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for PeptiDream's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PPTDF vs VRTX, REGN, ALNY: Debt-to-Equity Comparison
For the Biotechnology subindustry, PeptiDream's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PeptiDream Debt-to-Equity vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, PeptiDream's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where PeptiDream's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PeptiDream (PPTDF) has a Debt-to-Equity of 0.33 as of Mar. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on PeptiDream and its competitors. This is 35% below median its historical median of 0.51. Over the past decade, PeptiDream's Debt-to-Equity has ranged from 0.33 to 0.90. According to the industry distribution chart, PeptiDream ranks #626 out of 965 companies in the Biotechnology industry, placing it in the top 64.9%.
Is PeptiDream's Debt-to-Equity too high?
PeptiDream's current Debt-to-Equity of 0.33 is 35% below median its 10-year median of 0.51. Over the past 10 years, this metric has ranged from a low of 0.33 to a high of 0.90. The Biotechnology industry median Debt-to-Equity is 0.16. PeptiDream's value of 0.33 is 106.3% above this industry median. Based on the distribution chart, PeptiDream ranks #626 out of 965 companies in the Biotechnology industry, which is below the industry midpoint. Overall, PeptiDream has a GF Score™ of 76/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does PeptiDream's Debt-to-Equity compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, PeptiDream ranks #626 out of 965 companies for Debt-to-Equity. This places PeptiDream in the lower half of its industry. The industry median Debt-to-Equity is 0.16. PeptiDream's value of 0.33 is 106.3% above this benchmark. Historically, PeptiDream's own Debt-to-Equity has ranged from 0.33 to 0.90 over the past decade. While the company's 10-year median is 0.51 vs. the industry median of 0.16, PeptiDream has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Biotechnology company?
The median Debt-to-Equity among Biotechnology companies is 0.16, based on 965 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. PeptiDream's current Debt-to-Equity of 0.33 is 106.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on PeptiDream and its competitors. For the Biotechnology industry, the median Debt-to-Equity is 0.16 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. PeptiDream's current Debt-to-Equity is 0.33, which is 35% below median its own 10-year median of 0.51. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PeptiDream stock overvalued right now?
Based on GuruFocus' analysis, PeptiDream (PPTDF) is currently considered Possible Value Trap. The stock's GF Value™ is $10.57, compared to a current price of $5.99 — trading 43.3% below its estimated fair value. The current Debt-to-Equity is 0.33, which is 35% below median its 10-year median of 0.51 and 106.3% above the Biotechnology industry median of 0.16. PeptiDream's overall GF Score™ is 76/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For PeptiDream (PPTDF), the current Debt-to-Equity is 0.33 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is PeptiDream (PPTDF) Overvalued in 2026?
Based on GuruFocus' analysis, PeptiDream stock appears to be undervalued.
The current stock price of $5.99 is trading 43.3% below its estimated GF Value™ of $10.57.
GuruFocus considers PeptiDream to be Possible Value Trap.
Key valuation signals for PPTDF:
Debt-to-Equity: 0.33 (35% below median its 10-year median of 0.51)
GF Value™: $10.57 vs. price of $5.99 (43.3% below fair value)
Industry Position: 106.3% above the Biotechnology median (#626 of 965)
No single metric tells the full story. See the PPTDF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
PeptiDream Inc is engaged in the drug discovery and development business. The group utilizes PDPS, its proprietary drug discovery and development platform system, for drug discovery and development, and it conducts radiopharmaceutical business through a wholly owned subsidiary and is involved in the research, development, and manufacturing of pharmaceuticals, etc. Its reportable segments are Drug discovery and development business and Radiopharmaceutical business.
76GF Score
Get the complete analysis for PPTDF
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PPTDF has been successfully added to your 
